Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1162

1.

Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Awad AG, Voruganti LN.

CNS Drugs. 2004;18(13):877-93. Review.

PMID:
15521791
2.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
3.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
4.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

5.
6.

Measuring quality of life in patients with schizophrenia.

Awad AG, Voruganti LN, Heslegrave RJ.

Pharmacoeconomics. 1997 Jan;11(1):32-47. Review.

PMID:
10172917
7.

Atypical antipsychotic drugs and long-term outcome in schizophrenia.

Weiden P, Aquila R, Standard J.

J Clin Psychiatry. 1996;57 Suppl 11:53-60. Review.

PMID:
8941171
8.

Practical issues with amisulpride in the management of patients with schizophrenia.

Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.

Clin Drug Investig. 2008;28(8):465-77. Review.

PMID:
18598092
9.

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Naber D, Lambert M.

CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.

PMID:
19594194
10.

Quality of life and new antipsychotics in schizophrenia. Are patients better off?

Awad AG, Voruganti LN.

Int J Soc Psychiatry. 1999 Winter;45(4):268-75.

PMID:
10689610
11.

Children with schizophrenia: clinical picture and pharmacological treatment.

Masi G, Mucci M, Pari C.

CNS Drugs. 2006;20(10):841-66. Review.

PMID:
16999454
12.

[A rare and not very studied disorder: childhood-onset schizophrenia. A case report].

Bailly D, de Chouly de Lenclave MB.

Encephale. 2004 Nov-Dec;30(6):540-7. French.

PMID:
15738856
13.

[Leponex, 10 years after -- a clinical review].

Llorca PM, Pere JJ.

Encephale. 2004 Sep-Oct;30(5):474-91. Review. French.

PMID:
15627052
14.
15.
16.

The new and evolving pharmacotherapy of schizophrenia.

Emsley R, Oosthuizen P.

Psychiatr Clin North Am. 2003 Mar;26(1):141-63. Review.

PMID:
12683264
17.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
18.

[New chemotherapy approaches to psychoses].

Olié JP, Baylé FJ.

Encephale. 1997 Apr;23 Spec No 2:2-9. Review. French.

PMID:
9273302
19.

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.

Haro JM, Salvador-Carulla L.

CNS Drugs. 2006;20(4):293-301. Review.

PMID:
16599647
20.

Amisulpride: a review of its use in the management of schizophrenia.

McKeage K, Plosker GL.

CNS Drugs. 2004;18(13):933-56. Review.

PMID:
15521794
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk